Therapeutic Hypothermia After Pediatric Cardiac Arrest (IRB# 35927)
Cardiac arrest (CA) in childhood is a tragic event that often results in either death or poor quality neurological survival. The hypotheses of the THAPCA Trials are that
(1) therapeutic hypothermia will improve survival and neurobehavioral outcome following out-of-hospital cardiac arrest in children (THAPCA-OH Trial); and
(2) therapeutic hypothermia will improve survival and neurobehavioral outcome following in- hospital cardiac arrest in children (THAPCA-IH Trial).
These hypotheses will be tested independently. HMC will be participating in the "in-hospital" trial only.
Inclusion: Patients will be eligible for enrollment if they meet all of the following criteria:
- suffered cardiac arrest requiring chest compressions for at least 2 minutes (120 seconds) with ROSC/ROC
- age greater than 48 hours (with a corrected gestational age of at least 38 weeks) and less than 18 years
- patient requires continuous mechanical ventilation
- the cardiac arrest was unplanned (i.e., not part of cardiac surgical procedure)
Additional Study Details:
After eligibility is determined, consented participants will be randomized (1:1) to one of the two study groups:
¿ Hypothermia:body temperature is reduced to 89-93°F (32-34°C) for 48hrs
¿ Normothermia (normal body temperature): body temperature will be kept in a normal range 96-99°F (36.0-37.5°C) for 48 hrs